Regulus Therapeutics Announces First Patient Dosed In Second Cohort Of Phase 1b Multiple-Ascending Dose Clinical Trial Of RGLS8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Portfolio Pulse from Happy Mohamed
Regulus Therapeutics has dosed the first patient in the second cohort of the Phase 1b MAD study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The trial is progressing well, with topline data from the first cohort expected around the end of Q3.
June 27, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regulus Therapeutics progresses in Phase 1b MAD study of RGLS8429 for ADPKD treatment, with topline data from the first cohort expected by the end of Q3.
The dosing of the first patient in the second cohort of the Phase 1b MAD study is a positive development for Regulus Therapeutics. The trial's progress and the expected release of topline data from the first cohort by the end of Q3 could potentially have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100